TRPC4AP

Across TCGA pan-cancer cohorts, TRPC4AP mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRPC4AP data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRPC4AP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRPC4AP expression acts as an unfavorable survival marker.

PDAC, LSCC, and CCRCC are the cancer types where TRPC4AP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.238	0.447	.011	6	view →
LSCC	DFS	Tertile	All	0.605	1.000	.013	3	view →
CCRCC	DFS	Median	III,IV	0.619	0.915	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRPC4AP–PDAC (DFS)

Open the PDAC breakdown →